# A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold

> **NCT06697886** · PHASE3 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 480 (estimated)

## Conditions studied

- Common Cold

## Interventions

- **DRUG:** Antiwei Granules
- **DRUG:** Antiwei Granules Placebo

## Key facts

- **NCT ID:** NCT06697886
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-07-01
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697886, "A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06697886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*